MD Anderson Cancer Center

PDS Biotechnology to Present at the Benzinga Healthcare Conference

Monday, September 27, 2021 - 1:30pm

FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.
  • PDS Biotech management will deliver a presentation providing an update on the three ongoing PDS0101 Phase 2 clinical trials.
  • Following the presentation, President and Chief Executive Officer of PDS Biotech, Dr. Frank Bedu-Addo, will join a panel of leading oncology experts discussing the future of oncology.
  • Details for the presentation and panel are as follows:
    Benzinga Healthcare Small Cap Conference:
    Following the conference a webcast replay of the presentation will be available on the Investor section of the companys website, PDS Biotechnology .

Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference

Monday, September 27, 2021 - 1:03pm

Additionally, Mr. Arthur and members of the Salarius management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical company executives.

Key Points: 
  • Additionally, Mr. Arthur and members of the Salarius management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical company executives.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.
  • Salarius lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options.
  • Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers.

AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

Monday, September 27, 2021 - 1:00pm

The data was announced as a keynote presentation at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting on September 25-29, 2021.

Key Points: 
  • The data was announced as a keynote presentation at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting on September 25-29, 2021.
  • The scientific presentation entitled: Taletrectinib (AB-106): Preliminary results from TRUST, Phase trial of a new generation of potent ROS1/NTRK inhibitors in ROS1-positive non-small cell lung cancer (NSCLC), summarized preliminary data from an ongoing Phase trial of taletrectinib (NCT04395677).
  • Our team is focused on completing patient enrollment for our Phase TRUST trial, said Bing Yan, MD, Co-founder and Chief Medical Officer at AnHeart Therapeutics.
  • The interim data presented builds a strong foundation for our ongoing global pivotal taletrectinib clinical program.

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

Monday, September 27, 2021 - 11:00am

The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

Friday, September 24, 2021 - 12:30pm

VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.
  • The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks.
  • Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches.
  • At June 30, 2021, the Companys total issued and outstanding shares were 8,050,707.

DGAP-News: Abivax presents first-half 2021 financial results and operations update

Thursday, September 23, 2021 - 5:23pm

2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.

Key Points: 
  • 2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.
  • Cash at the end of June 2021 was EUR 4.3M, compared to EUR 29.3M at the end of 2020, before taking into account the EUR 85M financing realized in July 2021.
  • In March 2021, Abivax announced it would be stopping the phase 2b/3 Covid-19 study (miR-AGE trial - ABX464-401) due to lack of efficacy.
  • Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors.

Humana and Kelsey-Seybold Clinic Team up to Expand Access to Value-based Care, Broadening Humana’s Medicare Advantage Provider Network in the Greater Houston Area

Thursday, September 23, 2021 - 4:00pm

Humana , a leading health and well-being company, and Kelsey-Seybold Clinic have signed an in-network agreement, expanding access to care to include members of Humana Medicare Advantage HMO plans.

Key Points: 
  • Humana , a leading health and well-being company, and Kelsey-Seybold Clinic have signed an in-network agreement, expanding access to care to include members of Humana Medicare Advantage HMO plans.
  • Humana Inc. is committed to helping our millions of medical and specialty members achieve their best health.
  • More than 500 physicians and allied health professionals practice at 26 locations in the Greater Houston area.
  • Kelsey-Seybold has many physicians in the Greater Houston area certified for excellence in diabetes and heart and stroke care by the NCQA.

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Thursday, September 23, 2021 - 11:00am

CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.

Key Points: 
  • CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.
  • The 6th Annual Cantor Global Healthcare Conference will include leading industry speakers and more than 300 presenting companies, one-on-one meetings, and panel discussions.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Wednesday, September 22, 2021 - 1:30pm

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.
  • The conference is taking place virtually from September 27 - 30, 2021.
  • Details for the presentation are as follows:
    Cantor Fitzgerald Virtual Global Healthcare Conference:
    Following the conference a webcast replay of the presentation will be available on the Investor section of the companys website, PDS Biotechnology .
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform.

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Wednesday, September 22, 2021 - 1:00pm

We have developed HERKULES-3, our GI master protocol, to evaluate ERAS-007 in rational combinations to assess the possibility of reducing susceptibility to resistance and increasing durability of treatment.

Key Points: 
  • We have developed HERKULES-3, our GI master protocol, to evaluate ERAS-007 in rational combinations to assess the possibility of reducing susceptibility to resistance and increasing durability of treatment.
  • Another 45-50% of CRC patients have tumors that harbor KRAS or NRAS mutations, for which there is currently no approved targeted therapeutic option.
  • HERKULES-3 will examine the safety, tolerability, and preliminary efficacy of ERAS-007 in combination with other cancer therapies in study participants with GI malignancies.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.